vibrovax bivalent bovine vibriosis vaccine bivalent oily vibrio (campylobacter) fetus type 1 and subtype 1
csl limited - campylobacter felus (vibro fetus) venerealis biotype 1 | campylobacter fetus venerealis biotype intermedius subt1 - immunotherapy - bull | cow | heifer (young female cattle) | bovine | cow young | female cattle | male cattle - vaccines and antisera | brown snake bite | cheesy gland | enterotoxaemia | tetanus
tygacil
pfizer pharmaceuticals israel ltd - tigecycline - lyophilized powder for infusion - tigecycline 50 mg/dose - tigecycline - tigecycline - tygacil is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below for patients 18 years of age and older:complicated skin and skin structure infections:complicated skin and skin structure infections caused by escherichia coli, enterococcus faecalis (vancomycin-susceptible isolates ), staphylococcus aureus (methicillin-susceptible and -resistant isolates), streptococcus agalactiae, streptococcus anginosus grp. (includes s. anginosus, s. intermedius, and s. constellatus), streptococcus pyogenes, enterobacter cloacae, klebsiella pneumoniae, and bacteroides fragilis .complicated intra-abdominal infections:complicated intra-abdominal infections caused by citrobacter freundii, enterobacter cloacae, escherichia coli, klebsiella oxytoca, klebsiella pneumoniae, enterococcus faecalis (vancomycin-susceptible isolates), staphylococcus aureus (methicillin-susceptible and -resistant isolates), streptococcus anginosus grp. (includes s. anginosu
meronem 500 mg
pfizer pfe pharmaceuticals israel ltd - meropenem as trihydrate - powder for solution for injection - meropenem as trihydrate 500 mg/vial - meropenem - meropenem - meronem is indicated for treatment in adults and children of the following severe infections caused by single or multiple susceptible bacteria sensitive to meropenem: - pneumonias and nosocomial pneumonias. - pulmonary infections in patients with cystic fibrosis. - urinary tract infections. - intra-abdominal infections. - gynecological infections such as endometritis and pelvic inflammatory disease. - skin and skin structure infections. - meningitis. - septicemia. meronem has proved efficacious alone or in combination with other antimicrobial agents in the treatment of polymicrobial infections. there is no experience in pediatric patients with neutropenia or primary or secondary immunodeficiency.
meronem 500 mg
pfizer pfe pharmaceuticals israel ltd - meropenem as trihydrate - powder for solution for injection - meropenem as trihydrate 500 mg/vial - meropenem - meropenem - meronem is indicated for treatment in adults and children of the following severe infections caused by single or multiple susceptible bacteria sensitive to meropenem: - pneumonias and nosocomial pneumonias. - pulmonary infections in patients with cystic fibrosis. - urinary tract infections. - intra-abdominal infections. - gynecological infections such as endometritis and pelvic inflammatory disease. - skin and skin structure infections. - meningitis. - septicemia. meronem has proved efficacious alone or in combination with other antimicrobial agents in the treatment of polymicrobial infections. there is no experience in pediatric patients with neutropenia or primary or secondary immunodeficiency.
meronem 1 g.
pfizer pfe pharmaceuticals israel ltd - meropenem as trihydrate - powder for solution for injection - meropenem as trihydrate 1000 mg/vial - meropenem - meropenem - meronem is indicated for treatment in adults and children of the following severe infections caused by single or multiple susceptible bacteria sensitive to meropenem: - pneumonias and nosocomial pneumonias. - pulmonary infections in patients with cystic fibrosis. - urinary tract infections. - intra-abdominal infections. - gynecological infections such as endometritis and pelvic inflammatory disease. - skin and skin structure infections. - meningitis. - septicemia. meronem has proved efficacious alone or in combination with other antimicrobial agents in the treatment of polymicrobial infections. there is no experience in pediatric patients with neutropenia or primary or secondary immunodeficiency.
meronem 1 g.
pfizer pfe pharmaceuticals israel ltd - meropenem as trihydrate - powder for solution for injection - meropenem as trihydrate 1000 mg/vial - meropenem - meropenem - meronem is indicated for treatment in adults and children of the following severe infections caused by single or multiple susceptible bacteria sensitive to meropenem: - pneumonias and nosocomial pneumonias. - pulmonary infections in patients with cystic fibrosis. - urinary tract infections. - intra-abdominal infections. - gynecological infections such as endometritis and pelvic inflammatory disease. - skin and skin structure infections. - meningitis. - septicemia. meronem has proved efficacious alone or in combination with other antimicrobial agents in the treatment of polymicrobial infections. there is no experience in pediatric patients with neutropenia or primary or secondary immunodeficiency.
meronem 1 grams pdr for soln inj/inf
astrazeneca uk limited - meropenem trihydrate - pdr for soln inj/inf - 1 grams - carbapenems
meronem i.v. 500 milligram pdr for soln inj/inf
astrazeneca uk limited - meropenem trihydrate - pdr for soln inj/inf - 500 milligram - carbapenems
doribax™ powder for injection 500mg
celltrion healthcare singapore private limited - doripenem monohydrate - injection, powder, lyophilized, for suspension - 500 mg - doripenem monohydrate 500 mg
avelox solution for infusion 400 mg250 ml
bayer (south east asia) pte ltd - moxifloxacin hcl eqv moxifloxacin - injection - 400 mg/250 ml - moxifloxacin hcl eqv moxifloxacin 400 mg/250 ml